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Abstract: Functional and structural age-associated changes in the blood-brain barrier (BBB) may affect
theneurovascularunit and contribute to theonset andprogressionof age-associatedneurodegenerative
pathologies, including Alzheimer’s disease. The current study interrogated the RNA profile of the
BBB in an ageing human autopsy brain cohort and an ageing mouse model using combined laser
capture microdissection and expression profiling. Only 12 overlapping genes were altered in the
same direction in the BBB of both ageing human and mouse cohorts. These included genes with roles
in regulating vascular tone, tight junction protein expression and cell adhesion, all processes prone to
dysregulation with advancing age. Integrated mRNA and miRNA network and pathway enrichment
analysis of the datasets identified 15 overlappingmiRNAs that showed altered expression. In addition
to targeting genes related to DNA binding and/or autophagy, many of the miRNAs identified play
a role in age-relevant processes, including BBB dysfunction and regulating the neuroinflammatory
response. Future studies have the potential to develop targeted therapeutic approaches against these
candidates to prevent vascular dysfunction in the ageing brain.
Keywords: ageing; blood brain barrier; gene expression; miRNA
1. Introduction
The blood-brain barrier (BBB), formed by capillary endothelial cells, the basement membrane
and surrounding pericytes and astrocyte endfeet, is a highly specialised structure that maintains
homeostasis within the central nervous system (CNS) by regulating the bidirectional flow of molecules
between the circulation and the brain parenchyma [1]. Functional and structural age-associated
BBB changes may affect the neurovascular unit (NVU), impacting vascular integrity and resulting in
alterations in the perivascular environment, neuronal function and the neuroinflammatory response,
as demonstrated in both human and mouse studies [2–4].
BBB dysfunction, a reduction in cerebral blood flow and impaired haemodynamic responses are
prominent features of a range of neurodegenerative diseases, including Alzheimer’s disease (AD) [5,6].
In addition to the findings of several post-mortem tissue studies [7–9], neuroimaging approaches have
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demonstrated that dysfunction of the BBB is a feature of ageing [10], mild cognitive impairment and
early AD [11,12]. Moreover, increased permeability of the BBB precedes the formation of senile plaque
formation in an animal model of AD [13]. Together, these data support the vascular hypothesis of
AD [14–16], and suggest that BBB dysfunction, which can occur before the clinical manifestation of
dementia, is a prospective therapeutic target.
The continued advancement of transcriptomic profiling techniques, including microarray analysis,
has enabled the identification of specific gene expression changes and biological processes associated
with ageing [17–21]. Laser capturemicrodissection (LCM) enables the isolation of regions or enrichment
of specific cell types from post-mortem material and has been used in conjunction with transcriptomic
analysis in both human and animalmodel ageing studies to identify differentially expressed genes in the
hippocampus [22], and in enriched populations of LCM-isolated neurones [23–25] and astrocytes [26].
While LCM has been used to selectively study the transcriptomic profile of LCM-isolated vessels
in neurocysticercosis [27,28], glioblastoma [29,30], multiple sclerosis [31] and schizophrenia [32], to
date no studies have employed this approach to identify gene expression changes associated with
normal ageing.
MicroRNAs (miRNAs) are small, non-coding RNA molecules (containing approximately 22
nucleotides) that target genes in a sequence-specific manner to modulate gene expression, mainly by
degradation of mRNA or repression of expression [33,34]. They have recently been shown to target
genes which regulate BBB permeability in animal models of ischaemic stroke [35] and human brain
microvascular endothelial cells in vitro [36], indicating a role for miRNAs in modifying the integrity of
the BBB.
Our previous histological characterisation of ageing human and mouse cohorts provides evidence
of BBB dysfunction, loss of pericyte coverage and astrogliosis in normal human and murine brain
ageing [37]. The current study extends these findings and investigates age-associated changes in the
transcriptomic and miRNA profile of the NVU in ageing human and mouse cohorts, with the aim of
defining age-associated gene expression changes and identifying potential targets to improve healthy
brain ageing.
2. Results
2.1. Age-Associated Gene Expression Changes in the BBB
Gene expression analyses are sensitive to the presence of sample outliers, therefore rigorous
quality control procedures were used to ensure the highest possible level of quality for both the
human and mouse microarray datasets. Three human and two mouse arrays failed the quality control
protocols due to a low number of present calls and were excluded from the analysis. The data was
re-analysed after these cases were removed. All significant age-associated mRNA expression changes
in the BBB of humans and mice are freely available at Gene Expression Omnibus (human array data
accession number GSE127710 and mouse array data accession number GSE127709).
The number of significantly down-regulated genes in the BBB was higher than significantly
up-regulated genes in human old age samples when compared to the young (299 up, 516 down,
p < 0.01) and middle age groups (232 up, 604 down, p < 0.01). In contrast, the number of significantly
up-regulated genes in the BBB was higher than down-regulated genes in the mouse 24-month age
group when compared to either the 3 month (355 up, 37 down, p < 0.01) or 12 month time points
(471 up, 98 down, p < 0.01) (Figure 1a). Analysis of significantly, differentially expressed genes that
were altered in the same direction in both mouse and humans with ageing revealed little overlap,
with 12 overlapping genes (Rho GTPase-activating protein 42 (ARHGAP42), Down syndrome cell
adhesion molecule (DSCAM), endoplasmic reticulum lectin 1 (ERLEC1), glutamate ionotropic receptor
NMDA type subunit 2C (GRIN2C), huntingtin (HTT), myocardial infarction associated transcript
(MIAT), PHD finger protein 20 like 1 (PHF20L1), Snail family transcriptional repressor 2 (SNAI2),
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spectrin β, non-erythrocytic 1 (SPTBN1), protoporphyrinogen oxidase (PPOX), R3H domain containing
1 (R3HDM1) and histone-binding protein RBBP4 (RBBP4))(Figure 1b).

 
Figure 1. mRNA gene expression analysis. (a) Total number of significantly differentially expressed
probe sets and the ratio of up to down regulated transcripts in an ageing human and mouse cohort.
(b) The number of unique and overlapping significantly, differentially expressed genes between the
human and mouse datasets. Common genes, dysregulated in the same direction, between species are
listed. Up and down regulation compared to oldest age group are represented with directional arrows.
2.2. Pathway Enrichment Reveals Age-Related Changes in Genes Associated with DNA Binding and
Apoptosis/Autophagy
Analysis of genes grouped by molecular function optimises false negative and false positive
rates [38]; therefore we employed EnrichR and DAVID to interrogate the top 1000 genes from each
comparison in both the human and mouse datasets either by fold change or by p-value in order to
identify common pathways/functional groups affected by ageing. In the human dataset, analysis of the
genes sorted by fold change identified 447 significantly, differentially expressed genes common to all
three age group comparisons (Figure 2a), and by p-value identified 353 genes (Figure 2b). In the mouse
dataset, analysis of the genes sorted by fold change identified 52 significantly, differentially expressed
genes common to all three comparisons (Figure 2c), and by p-value identified 150 genes (Figure 2d).
The overlapping gene lists from each analysis were inputted into DAVID, with the aim of
identifying gene networks and clusters of functionally similar genes. In the human dataset, analysis of
the overlapping genes common to all three comparisons in the genes sorted by fold change identified
three clusters with an enrichment score greater than 1.3 (DNA binding, kelch-like, tRNA modification),
and in the genes sorted by p-value identified two clusters (DNA binding, apoptosis)(Table 1). In
the mouse dataset, analysis of the overlapping genes common to all three comparisons in the genes
sorted by p-value identified three clusters with an enrichment score greater than 1.3 (GTP binding,
Armadillo-like, ion channel binding)(Table 1), but did not identify any clusters in the genes sorted by
fold change using a high stringency filter.
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Figure 2. Analysis of top 1000 genes from each comparison in both the human and mouse datasets.
In the human dataset, analysis of the genes sorted (a) by fold change identified 447 significantly,
differentially expressed genes common to all three comparisons, and (b) by p-value identified 353
genes. In the mouse dataset, analysis of the genes sorted (c) by fold change identified 52 significantly,
differentially expressed genes common to all three comparisons, and (d) by p-value identified 150 genes.
To further analyse the data, the 353 human genes and 150 mouse genes from the overlapping
genes common to all three comparisons in the genes sorted by p-value were assessed using EnrichR.
Both the Reactome 2016 database and GO biological process indicated that both lists were significantly
enriched for BH3-only proteins, which play an important role in initiating apoptosis and autophagy.
Analysis of the human dataset identified: BCL2-like 11 (BCL2L11), BCL2 associated agonist of cell
death (BAD) and tumor protein p53 (TP53), p = 0.0069 (Reactome 2016) and p = 0.0036 (GO biological
process). Analysis of the mouse dataset identified: protein phosphatase 3 catalytic subunit gamma
(PPP3CC), catenin beta 1 (CTNNB1), BH3 interacting domain death agonist (BID) and karyopherin
subunit alpha 1 (KPNA1), p = 0.0073 (Reactome 2016).
2.3. Age-Associated miRNA Expression Changes in the Ageing BBB
In the human miRNA data analysis, 256 miRNAs were differentially altered in the same direction
when the oldest group was compared to the younger cohort, and in the mouse analysis, 244 miRNAs
were altered in the same direction. All significant age-associated miRNA expression changes in the BBB
of human and mice are freely available at Gene Expression Omnibus. From these results, 15 miRNAs
were identified that overlapped and showed altered expression in the ageing NVU of both species
(miR-653-5p, miR-302a-5p, miR-206, miR-183-5p, miR-182-5p, miR-100-3p, miR-96-5p, miR-3065-3p,
miR-1298-5p, miR-615-3p, miR-511-5p, miR-499-5p, miR-345-5p, miR-155-5p, miR-27a-5p), as shown in
Figure 3.
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Table 1. Gene network and cluster analysis of differentially expressed genes common to all three
comparisons (young versus old; young versus middle aged; middle aged versus old) in both the human
and mouse datasets, selected by fold change and by p-value.
Dataset Cluster No. Genes Enrichment Score
Human (sorted by FC) DNA binding 6 1.88
Kelch-like 5 1.73
tRNA modification 4 1.46
Human (sorted by p-value) DNA binding 5 1.45
Apoptosis 3 1.32
Mouse (sorted by p-value) GTP binding 7 2.32
Armadillo-like 4 1.81
Ion channel binding 3 1.76
FC, fold change.

Figure 3. miRNA expression analysis. (a) miRNA expression in the human and mouse age group
comparisons. Numbers of overlapping miRNAs within species and between all four comparisons are
indicated in appropriate sections. (b) fold change profiles for the panel of 15 overlapping miRNAs
between species.
The Targetscan software was used to specifically identify miRNAs with target genes relating to
DNA binding and autophagy (identified in the human mRNA analysis). The miRNAs targeting genes
related to autophagy were miR-181c-3p and 505-5p which target TP53 and miR-505-5p which targets
arylsulfatase A (ARSA), while those targeting genes related to DNA binding are shown in Table 2.
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Table 2. miRNAs which target genes relating to DNA binding. The shaded box indicates that a gene is present in the list of targets of the miRNA. This comparison has
a highly significant p-value of 1 × 10−12. All but two of the genes present in the list are targets of more than one miRNA.
miRNA Gene Target 1298-5p 653-5p 511-3p 505-5p 345-5p 302a-5p 224-5p 205-5p 182-5p 181c-3p 155-5p 100-3p 27a-5p Total
NFIB 9
ZNF704 7
EBF1 6
FOXP1 6
IKZF1 5
ZFHX4 4
FLI1 4
ATF6 4
HNRNPD 4
MAFF 4
RCOR3 3
ZKSCAN3 3
ZNF514 3
FOXA1 2
ZNF268 2
ZNF90 2
TP53 2
RAD51D 2
ERCC1 2
ZNF600 2
FOXR2 1
TCF7L1 1
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2.4. qPCR and Immunohistochemistry Validation of Age-Associated Candidate Gene Expression Changes
Validation candidates were selected from the initial microarray analysis based upon species
overlap (GRIN2C and SNAI2), and functional overlap with large fold changes (CDC42 binding protein
kinase-β (CDC42BPB): fold change (FC) = 5.41). Additional validation candidates were selected from
the DNA binding (Activating Transcription Factor 6 (ATF6) and zinc finger protein 90 (ZNF90)) and
apoptosis/autophagy (beclin 1 (BECN1), RB1-inducible coiled-coil 1 (RB1CC1), tumor protein p53 (TP53)
clusters identified by the DAVID and EnrichR analyses. Consistent with microarray results, qPCR
analysis revealed a similar but non-significant directional change in expression of GRIN2c (p = 0.078),
CDC42BPB (p = 0.142), ATF6 (p = 0.056) and ZNF90 (p = 0.611) in the ageing human BBB (Figure 4).

Ά
Figure 4. qPCR for mRNA validation of gene expression. A non-significant increase in (a) GRIN2C
(p = 0.078), (b) CDC42BPB (p = 0.142), (c) ATF6 (p = 0.056) and a non-significant decrease in (d) ZNF90
gene expression was detected in the BBB of the old group, similar to the directional change observed in
the microarray analysis. Data presented as mean ± standard error of the mean (SEM).
Immunohistochemistry confirmed expression of the protein encoded by the candidate genes was
associated with the BBB. Immunostaining for SNAIL, encoded by SNAI2, Figure 5a and p53, encoded
by TP53, Figure 5b revealed a predominantly nuclear specific signal that was present in a proportion
of all cell types, including the BBB where immunoreactive endothelial cell nuclei were identified
by their location and typical elongated shape. Immunoreactivity for RB1CC1 was predominantly
associated with capillaries as shown in Figure 5c. In addition to endothelial immunoreactivity, beclin-1
cytoplasmic staining of pyramidal neurones was present throughout the cortex, Figure 5d.
qPCR demonstrated the same directional change of expression for miR-155-5p (Figure 6a,b),
miR-1298-5p (Figure 6c,d) and miR-182-5p (Figure 6e,f) in both the human and mouse ageing groups,
consistent with the directional change observed in the miRNA analysis. Only the age change in
miR-182-5p in human samples achieved statistical significance in the oldest group (p = 0.032).
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Figure 5. Investigation of protein expression by candidate genes identified in array analysis. (a) SLUG
(SNAI2) and (b) p53 (TP53) immunolabelled a proportion of endothelial cell nuclei. (c) Immunoreactivity
for RB1CC1 (RB1CC1) was predominantly associated with the basement membrane of capillaries.
(d) In addition to endothelial immunoreactivity, beclin-1 (BECN1) cytoplasmic staining of pyramidal
neurones (examples indicated by the open arrow) was present throughout the cortex (Figure 6d).
Immunopositive staining of the BBB is indicated by the black arrow. Scale bar represents 50 µm (a,b,c)
or 100 µm (d).


Figure 6. qPCR validation of miRNA expression. qPCR demonstrated the same directional change of
expression for all three candidates (miR-155-5p (a,b); miR-1298-5p (c,d); miR-182-5p (e,f)) in both the
human (a,c,e) and mouse (b,d,f) groups, similar to the directional change observed in the microarray
analysis. Only miR-182-5p in human samples was significantly altered (ANOVA p = 0.032). Data
presented as mean ± SEM.
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3. Discussion
Vascular pathology and dysfunction of the NVU may contribute to the onset and progression
of AD [39], however the molecular mechanisms underpinning these changes in the ageing brain
are poorly defined. Using a combined LCM and expression profiling approach, the current study
characterised age-associated changes in the RNA profile of the NVU in an ageing mouse model and an
ageing human cohort, identifying mRNA and miRNA expression changes at the NVU which suggest a
role for the dysregulation of autophagy and DNA binding in age-associated vascular pathology.
High throughput RNA expression technology enables the use of genome-wide approaches to
explore and identify differences in biological conditions, such as ageing. We report that the overall
number of significantly down-regulated genes was higher in human old age samples when compared
to the young samples. This observation suggests that ageing negatively impacts the transcriptome and
may result in an overall age-associated decline in function in the NVU. The high number of upregulated
genes in the mouse ageing cohort however, may reflect a developmental expression profile or species
difference [40].
Only 12 overlapping genes were altered in the same direction in the NVU of both ageing
human and mouse cohorts, including genes which play an important role in regulating vascular tone
(ARHGAP42) [41]; cell adhesion, neurite outgrowth andaxonguidance (DSCAM) [42]; repression of tight
junction protein expression (SNAI2) [43,44]; cellular stress-response (ERLEC1) [45]; learning, memory
and synaptic development (GRIN2C) [46], all processes prone to dysregulation with advancing age.
Given the low number of overlapping specific candidate genes, we employed integrated mRNA
and miRNA network and pathway enrichment analysis of the ageing mouse and human NVU
datasets, and identified transcriptomic changes associated with DNA binding and apoptosis/autophagy
pathways. The major miRNA-targeted genes associated with DNA binding included zinc finger
proteins (ZNF), activating transcription factor (ATF) and the Forkhead family of transcription factors
(FOX). ZNF have a wide range of functions including interacting with DNA to regulate transcription, as
reviewed in [47]. In the current study we identified dysregulated expression of several members of the
ZNF family, including ZNF704, which is a suggested potential candidate gene for healthy ageing [48],
and ATF6, a member of the leucine zipper family of transcription factors which plays a major role in
regulating tissue homeostasis in response to stress [49], and is expressed at high levels in a range of
neurodegenerative diseases including amyotrophic lateral sclerosis [50]. We also report dysregulated
expression of several members of the FOX transcription factors, including FOXA1which plays a role in
the response to stress and is associated with the AD-gene signature [51] and FOXP1which regulates
expression of immune genes [52]. Together these findings suggest that dysregulation of DNA binding
genes which regulate transcription of stress response and immune response-related genes may be an
early event in age-associated changes at the NVU.
Several studies indicate dysregulation of autophagy, a lysosome-dependent process in which
organelles and proteins are degraded, as a contributing factor to the pathogenesis of AD, as recently
reviewed [53], with autophagy-associated markers detected in vessels in AD [54] and impaired
autophagic protein degradation associated with apoptosis of endothelial cells [55]. In addition to
identifying dysregulation of autophagy-associated BECN1 and the apoptosis-related gene TP53, we
also confirmed endothelial expression of beclin-1 and p53 by endothelial cells, supporting the findings
of previous studies [56,57], and suggesting that dysregulation of the apoptosis/autophagy pathway
may contribute to dysfunction of the NVU in the ageing brain.
miRNAs regulate a diverse range of biological processes by interacting with their target mRNA,
usually to repress translation [58]. In the current study, integrated analysis of miRNA and mRNA
expression profiling identified 15 miRNAs that overlapped and showed altered expression in the
ageing NVU of both species. In addition to targeting genes related to DNA binding and/or autophagy,
many of these well characterised miRNAs play a role in several age-relevant processes. We report
increased expression of miR-155, one of the most well characterised miRNAs, which has also been
detected in patients and animal models of AD [59] and Down syndrome dementia [60,61], and has
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been shown to play a role in regulating the neuroinflammatory response in AD [62] and contributing
to BBB dysfunction in multiple sclerosis [63] and cerebral malaria [64]. While the majority of miR-345
studies to date have focussed on the role in the induction of apoptosis in cancer [65,66], miR-345-5p
has been identified as a potential blood biomarker in multiple sclerosis patients [67], indicating that
this miRNA plays a role in neurological disease. Interestingly miR-27a has recently been shown to
protect against BBB dysfunction in a mouse model of intracerebral haemorrhage [68] and to protect
against traumatic brain injury by suppressing autophagy [69], suggesting that the significant increased
expression of miR-27a in the ageing NVU may play a neuroprotective role.
Several of the miRNAs identified in the analysis presented a significant reduction in expression,
including miR-96, which is associated with an increased neuroinflammatory response [70]; miR-100
which regulates expression of major components of the mechanistic target of rapamycin (mTOR),
transforming growth factor-β and insulin signalling pathways in brain endothelial cells [71]; miR-182
and miR-183 which regulate SUMOylation and act to preserve homeostasis under stress [72]; and
miR-206, which is differentially expressed in patients with mild cognitive impairment, as recently
reviewed [73].
While our study discusses our findings with respect to ageing, it should be acknowledged that
other factors may have influenced BBB dysfunction in the human cohort. For example, raised venous
pressure peri-mortem may have impacted the BBB in the youngest age group cases that died by
suspension ligature [74], and ischemic heart disease may have impacted the BBB in the older cohort [75].
Such co-morbidities are an inevitable limitation with human autopsy cohorts.
Animal models of ageing and age-associated disease are crucial to research and offer the
opportunity to identify novel molecular mechanisms underlying age-associated neuropathology,
however, the findings of the current study suggest that the data generated in these models should
be interpreted with caution as not all the candidates identified are relevant to human disease and
cannot be directly translated. Overall our integrated mRNA and miRNA network analysis of the NVU
transcriptome in ageing human and mouse cohorts identified dysregulation of apoptosis/autophagy
and DNA binding networks, in addition to biologically relevant RNA changes which impact BBB
function and CNS homeostasis. Future studies to interrogate these candidate changes in more detail
have the potential to develop targeted therapeutic approaches to prevent vascular dysfunction in the
ageing brain.
4. Materials and Methods
4.1. Study Cohort
Frozen samples of post mortem human prefrontal association cortex (Brodmann areas 8/9) from
cases without a history of neurological disease were obtained from the Edinburgh Medical Research
Council Sudden Death Brain Bank, who granted approval for the use of tissue in this study (Edinburgh
Brain Bank REC reference 11/ES/0022). The cohort represented young adult (20–30 years [y], n = 5),
middle aged (44–57 y, n = 5) and old aged individuals (71–79 y, n = 5). Haematoxylin and eosin stained
sections were examined from each case by a neuropathologist (S.B.W.), and immunohistochemistry
was carried out with antibodies phospho-tau (AT8) and β-amyloid, to document age-associated
pathological changes (Table 3).
C67BL/6 male mice were purchased from Charles River at 3, 12 and 24 months old (n = 5 per
group). Animals were sacrificed, perfused with phosphate buffered saline (PBS) and the brain dissected
and snap frozen in liquid nitrogen. All animal experiments were conducted following ethical review
processes in accordancewith the Animals (Scientific Procedures) Act 1986 of the UK government (Home
Office Project Licence Number 8002612, approval date 30th April 2013) and the ARRIVE guidelines
(Animal Research: Reporting of In Vivo Experiments: https://www.nc3rs.org.uk/arrive-guidelines).
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Table 3. Demographics of human cases used in gene expression analysis: age, gender, post-mortem
delay, brain pH, cause of death and neuropathology.
Age Group Age Gender PMD pH Cause of Death Neuropathology
Young
20 F 71 6.5 SBL None
24 F 47 6.4 SBL Small vessel disease
25 M 53 6.4 SBL None
29 M 44 6.5 SBL Focal Tau
30 M 71 6.4 NK None
Middle
aged
44 M 47 6.3 Drug overdose None
48 M 72 6.3 CAD None
50 M 45 6.3 IHD/CAD None
52 M 91 6.4 Road traffic collision None
57 M 66 6.5 IHD/CAD None
Old
71 F 41 6.5 IHD
Mild and focal vascular tau. Mild amyloid
tangles and plaques
74 M 46 6.3
Pulmonary
thromboembolism
None
74 M 66 6.3 IHD/CAD Mild tau tangles, plaques and threads.
75 M 78 6.4 IHD/CAD Mild tau tangles and threads
79 F 45 6.3 IHD/CAD Venous collagenosis and small vessel disease
Abbreviations: PMD: post-mortem delay in hours; M: male; F: female; SBL: suspension by ligature; NK: not known;
IHD: ischaemic heart disease; CAD: coronary artery disease.
4.2. Laser Capture Microdissection
Laser capture microdissection (LCM) of microvascular cells was performed using a standard
protocol [76]. Frozen sections (7 µm) were stained for Collagen IV (1:200, AbCam, UK ab6586) using
a rapid avidin-biotinylated complex-horse radish peroxidase complex (ABC-HRP) immunostaining
protocol to visualise vessels. Subsequently, sections were dehydrated in a graded series of ethanol,
extensively cleared in xylene and air dried for 1 h. Microvascular cells were microdissected using
an Arcturus Veritas Laser Capture Microdissection System (Arcturus Bioscience Inc., Mountainview,
CA, USA), and collected onto two thermoplastic-coated CapSure caps (ThermoFisher, Altrincham
UK) per sample. Following microdissection, caps were secured in 0.5 mL tubes, incubated with RNA
PicoPure® extraction buffer (Life Technologies, Paisley, UK) at 42 ◦C for 30 min. A work flow of the
study design is outlined in Figure 7.
4.3. Total RNA Extraction
The cell/extraction buffer solution from two caps per sample was combined, then divided equally.
For mRNA extraction, 50 µL of sample was taken through the PicoPure® RNA isolation protocol
according to the manufacturer’s instructions, with mRNA eluted in 10 µL of PicoPure® elution
buffer. For miRNA extraction, the remaining 50 µL of sample was passed through a Centri Spin™-10
purification column (Princeton Separations Inc, Adelphia, NJ, USA) according to manufacturer’s
instructions. All RNA samples were stored at −80 ◦C prior to expression profiling.
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Figure 7. Workflow of the study design, including initial mRNA and miRNA expression profiling,
bioinformatic analysis and validation. LCM: laser capturemicrodissection. IHC: immunohistochemistry.
qPCR: quantitative polymerase chain reaction.
4.4. mRNA Expression Profiling
Transcriptional profiling of the BBB isolated from an ageing mouse cohort was performed using
Affymetrix Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara, CA, USA). In the human cohort we
profiled samples using Human Genome U133 PLUS 2.0 Arrays (Affymetrix). Total RNA was annealed
to an oligo-d(T) primer with a T7 polymerase binding site. After generation of double-stranded cDNA,
copy RNA (cRNA) was transcribed which then formed the RNA template for a second round of
amplification. At the end of this round, after synthesis of double-stranded cDNA, biotin-labelled
cRNA was prepared using the Affymetrix Gene Chip (Affymetrix) in vitro transcription labelling kit.
Following clean-up of the biotin-labelled cRNA the material was assayed (Agilent Bioanalyser 2100,
Stockport, UK) to ensure sufficient RNA of appropriate quality had been prepared. Labelled cRNA
(12.5 µg) was fragmented, applied to the gene chips and hybridised over 16 h at 45 ◦C in a rotating
oven at 60 rpm. Post hybridisation washing and sample staining was carried out using the Fluidics
Station 400 and the Gene Chip Operating System (GCOS). Gene chips were scanned using the GC3000
7G scanner and data processed for quality control using Expression Console software (Affymetrix) and
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analysis carried out using Qlucore Omics Explorer (Qlucore, Lund, Sweden). Further analysis was
carried out using R statistical language as detailed below.
4.5. miRNA Expression Profiling
Extracted miRNA samples from each age group (3, 12 and 24 months in the mice and young,
middle, old in humans) were pooled. miRNA profiling was performed with miRNome miScript
miRNA PCR arrays (Qiagen, Hilden, Germany) in accord with the manufacturer’s recommendations,
using a CFX Real-Time PCR System instrument (Bio-Rad, Hercules, CA, USA). All miRNome qPCR
experiments were performed in 384 well plates, with a set of normalisation and technical controls
repeated on each plate.
4.6. Data Analysis: mRNA
Analysis of microarray output was conducted using the R statistical language with statistical
packages available from Bioconductor (LIMMA and PUMA) (www.bioconductor.org). Multi-chip
modified gamma model for oligonucleotide signal (MMGMOS) normalization, using median global
scaling, followed by present/absent MAS5 filtering, was applied to process the data. Subsequently,
the improved probability of positive log ratio (IPPLR) in PUMA was used to identify differentially
expressed genes between the age groups in each species, minimum 1.2 fold change (FC). In the
human data, the middle aged group comprised of exclusively male samples, to eliminate potential
influence of gender bias in the data a PUMA comparison of male versus female genes was completed
within the old age group, and significantly differentiated genes removed from further age group
comparisons. The gene lists were analysed by EnrichR and the Database for Annotation Visualisation
and Integrated Discovery bioinformatics programme (DAVID) was used to group genes according to
their function [77,78].
To further interrogate the data, the top 1000 genes from each comparison (young versus old; young
versus middle aged; middle aged versus old) in both the human and mouse datasets were selected
by fold change and by p-value and Venn diagrams created to highlight the significantly, differentially
expressed genes which appeared in all three comparisons. The gene lists from the centre of each Venn
diagram were analysed by EnrichR and DAVID using a high stringency filter to reduce the rate of false
positives, and an enrichment score >1.3 (corresponding to a p-value <0.05) considered significant.
4.7. Data Analysis: miRNA
Expression data for 1008 human miRNAs and 940 mouse miRNAs obtained from the Qiagen
miRNome PCR arrays was analysed using the HTqPCR package from Bioconductor [79]. Data was
filtered to remove miRNAs with a Ct value >37 in all samples. Geometric mean normalisation was
applied to each individual 384 well plate, followed by global normalisation using the quantile method
after data was combined to constitute each miRNome dataset. NormFinder analysis of internal
controls was used to identify the most stable genes (Human: SNORD61 and SNORD68, mouse:
SNORD68 and SNORD96A) for ∆Ct and fold change calculations using the ∆∆Ct method of relative
quantification. Subsequently, miRNAs were ranked according to fold change in age group comparisons
and considered differentially expression based on ≥1.5 fold change. Enrichment analysis using Diana
mir-Path software allowed identification of molecular pathways potentially altered by the expression
of multiple miRNAs. Target genes of these miRNAs were downloaded from Targetscan and compared
to the mRNA array datasets.
4.8. Quantitative PCR
RNAwas extracted from laser capturedmicrovessels using PicoPure RNA isolation kit as described
above and cDNA synthesized with the qScript cDNA supermix kit (Quanta Biosciences, Gaithersberg,
MD, USA) in a G-Storm thermocycler (G-Storm, Somerton, UK). In contrast to the miRNA array
profiling which was conducted on pooled samples from each age group, for qPCR individual samples
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in each age group were analysed. qPCR was performed using IDT PrimeTime qPCR assays (Integrated
DNA Technologies, Glasgow, UK) and Brilliant qPCR mix (Agilent) in a reaction volume of 5 µL using
a CFX Real-Time PCR System instrument (Bio-Rad) (Table 4). β-actin was amplified on each plate
to normalize expression levels of target genes using the ∆∆Ct method, and differences in mRNA or
miRNA expression assessed by student’s t-test or ANOVA, respectively.
Table 4. qPCR primer/probe sequence.
Gene Sequence
ATF6
Probe 5′-FAM/CATTCCTCCACCTCCTTGTCAGCC-3′
Primer 1 5′-CTTGGTCCTTTCTACTTCATGTCT-3′
Primer 2 5′-CCCTGATGGTGCTAACTGAA-3′
CDC42BPB
Probe 5′FAM/ACAAAGAGCCTGATTCGGACTCCAC-3′
Primer 1 5′-GGAGCTATTCGATGGAGTTGAG-3′
Primer 2 5′-GAACAAGCCCTACATCTCGTG-3′
GRIN2C
Probe 5′-FAM/ AAGGCATCCAGCTTCCCCATCTT-3′
Primer 1 5′-TTGAGGA -3′AGCAGCATCATAG-3′
Primer 2 5′-CGCAGTAACTACCGTGACAT-3′
ZNF90
Probe 5′-FAM/AGCTGTGGATCTCCCAATACCTGC-3′
Primer 1 5′-GGCCACATCTCTAAATTCCAATG-3′
Primer 2 5′-CTTAGCTGCTTCGTGTCTTCT-3′
ACTB
Probe 5′-FAM-CCATGTACGTTGCTATCCAGGCTGT-3′
Primer 1 5′-CCAGTGGTACGGCCAGA-3′
Primer 2 5′-GCGAGAAGATGACCCAGAT-3′
4.9. Immunohistochemistry
To confirm BBB expression of proteins encoded by the candidate genes, immunostaining was
performed using a standard avidin biotinylated enzyme complex (ABC) method, and the signal
visualised with diaminobenzidine (Vector Laboratories, Peterborough, UK). A summary of the primary
antibodies used is shown in Table 5.
Table 5. Antibody source and specificity.
Antibody Isotype Dilution Antigen Retrieval Supplier
Beclin-1 Rabbit IgG 1:250 (60 min, RT) PC EDTA AbCam
p53 Mouse IgG 1:50 (o/n, 4 ◦C) PC EDTA Santa Cruz
RB1CC1 Rabbit IgG 1:100 (60 min, RT) PC TSC Sigma Aldrich
SLUG Rabbit IgG 1:200 (60 min, RT) MW TSC AbCam
Abbreviations: RT: room temperature; o/n: overnight; PC: pressure cooker (125 ◦C for 30 s at 20 psi); MW:microwave;
EDTA: ethylenediaminetetraacetic acid (pH 8); TSC: trisodium citrate (pH 6.5).
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Abbreviations
ABC-HRP Avidin-biotinylated complex-horse radish peroxidase
AD Alzheimer’s disease
ARHGAP42 Rho GTPase-activating protein 42
ARSA arylsufatase A
ATF Activating Transcription Factor
BAD BCL2 associated agonist of cell death
BBB blood-brain barrier
BCL2L11 BCL2-like 11
BECN1 beclin 1
BID BH3 interacting domain death agonist
CDC42BPB CDC42 binding protein kinase-β
CNS central nervous system
CSF cerebrospinal fluid
CTNNB1 catenin beta 1
DAVID Database for Annotation Visualisation and Integrated Discovery
DSCAM Down syndrome cell adhesion molecule
EBF1 early B-Cell Factor 1
ERCC1 excision repair cross-complementation group 1
ERLEC1 endoplasmic reticulum lectin 1
FC fold change
FLI1 friend leukemia integration 1 transcription facto
FOX Forkhead family of transcription factors
GEO Gene Expression Omnibus
GFAP glial fibrillary acidic protein
GRIN2C glutamate ionotropic receptor NMDA type subunit 2C
HTT huntingtin
IKZF1 Ikaros family zinc finger protein 1
IPPLR improved probability of positive log ratio
KPNA1 karyopherin subunit alpha 1
LCM laser capture microdissection
MAFF v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F
MIAT myocardial infarction associated transcript
miRNA microRNA
MMGMOS multi-chip modified gamma model for oligonucleotide signal
mRNA messenger RNA
mTOR mechanistic target of rapamycin
NFIB nuclear factor I B
NFL neurofilament light
NVU neurovascular unit
PBS phosphate buffered saline
PHF20L1 PHD finger protein 20 like 1
PPOX protoporphyrinogen oxidase
PPP3CC protein phosphatase 3 catalytic subunit gamma
R3HDM1 R3H domain containing 1
RBBP4 histone-binding protein RBBP4
RB1CC1 RB1-inducible coiled-coil 1
RCOR3 REST Corepressor 3
SNAI2 Snail family transcriptional repressor 2
SPTBN1 spectrin β, non-erythrocytic 1
TCF7L1 transcription factor 7-like 1
TP53 tumor protein p53
vWF von Willibrand factor
ZFHX4 zinc finger homeobox 4
ZKSCAN3 zinc finger with KRAB and SCAN domains 3
ZNF zinc finger protein
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